TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 6, Issue 3, 2019
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
METHOD DEVELOPMENT AND VALIDATION OF ACECLOFENAC AND PREGABALIN IN MARKETED FORMULATION BY UPLC METHOD
Author
M. Ravisankar, Dr. S. Alexander, M.Shankar, Dr. E. Jeyaseeli Florance, Dr. R. Senthil Kumar
Email
pharmaravi18@gmail.com
keyword
Pregabalin, Aceclofenac, UPLC
Abstract
A Simultaneous estimation of UPLC method was established and validated for the estimation of Pregabalin and aceclofenac in tablet dosage form using Aquity UPLC HSS C18 column (100mm x 2.1mm, 1.8μ) 0.05 M phosphate buffer (pH- 6.2): Methanol : Acetonitrile (55 : 30 :15 v/v) with a flow rate of 0.3ml/min and UV detection at 218nm. Recovery was perceived 98.78% to 100.69 %.Accuracy of the method was observed to be within the limits of 98% to 102% by mean of 3 determinations. Precision of drugs was found to be less than 2.0 of %RSD from the mean of six preparations. Linearity was observed in the concentration range 100–600 µg/mL for Aceclofenac and 38–225 µg/mL for pregabalin. LOD and LOQ were found to be 9.85 and 3.03 µg/mL for Aceclofenac and Pregabalin, 29.86 µg/mL and 9.18 µg/mL for Aceclofenac and pregabalin respectively. The method was validated as per ICH guidelines.
Download Broucher
Back to Top >>>>